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Abstract
Promoting successful cognitive aging is a topic of major importance to individuals and the field of
public health. This review presents a coherent framework not only for evaluating factors,
protective activities, and enhancing agents that have already been proposed, but also ones that will
be put forward in the future. The promotion of successful cognitive aging involves the dual goals
of preventing loss of information processing capacity and cognitive reserve, and enhancing brain
capacity and cognitive reserve. Four major lines of evidence are available for evaluating whether a
proposed factor promotes successful cognitive aging: 1) epidemiologic/cohort studies; 2) animal/
basic science studies; 3) human “proof-of-concept” studies; and 4) human intervention studies.
Each line of evidence has advantages and limitations that will be discussed. Through illustrative
examples, we trace the ways in which each method informs us about the potential value of several
proposed factors. Currently, lines of converging evidence allow the strongest case to be made for
physical and cognitively stimulating activities. Although epidemiological data seem to favor the
use of statins to lower the risk of dementia, more definitive recommendations await further
randomized controlled studies. There is presently no clear evidence that antioxidants or Ginkgo
biloba promote successful cognitive aging. The impact of resveratrol, fish oil, and a long list of
other proposed agents needs to be determined. Clinicians remain well-positioned to identify and
aggressively treat vascular risk factors, diabetes, sleep disorders, and other conditions that may
reduce brain capacity, and to encourage activities that can build cognitive reserve.
Keywords
clinical research methods; cognition; cognitive reserve; dementia risk factors; neuroprotection;
successful aging
INTRODUCTION
This is a propitious time in which to review the topic of promoting successful cognitive
aging. In the face of shifting demographics, heightened awareness of the risk of cognitive
impairment and dementia, and strong marketing campaigns promising to slow the aging
process and increase cognitive powers, there is a pressing need to be able to separate fact
from fiction. Clinicians are increasingly being asked by their middle-aged and older patients
what can be done to retain their cognitive abilities and avoid becoming demented. Numerous
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ttheories and claims are being promulgated, and the cognitive enhancement business is
booming. The goal of this paper is to provide a coherent background for making sense of the
major issues associated with the field. It does not aim to complete an exhaustive review of
all proposed factors, protective activities, or enhancing agents, as these are very likely to
change over time. Rather, it will develop a framework in which to consider not only current
but also future possibilities.
DEMOGRAPHIC ISSUES
According to a recent UN report [1], individuals over the age of 60 are the fastest growing
age group on earth. They currently account for 700 million people around the world. By
2050, the numbers are expected to grow to 2 billion. In the US alone, there are over 75
million Baby Boomers (the cohort born between 1946 and 1964). In two years, the Boomers
will begin turning 65, and by 2030 the US population over 65 will double to more than 70
million. Members of this age group have been particularly concerned about maximizing
longevity and quality of life. Studies have suggested more than half of adults over the age of
65 have concerns about their memory [2–4]. Losing one’s mental faculties and
independence are among the most feared aspects of getting older. Moreover, caring for older
individuals who can no longer manage independently has become a major public health
issue [5].
NORMAL, NORMATIVE, AND SUCCESSFUL AGING
“Normal” cognitive aging entails predictable changes in cognition associated with getting
older. “Normative” cognitive aging represents a level of neuropsychological functioning that
falls within 1.5 or 2 standard deviations of the mean for age. One challenge to this concept
of normal cognitive aging is that a large portion of the population over the age of 85 exhibits
signs of clinical dementia [6,7]. Does that mean that dementia is a part of normal cognitive
aging? An alternative definition of normal cognitive aging suggests that it represents “non-
pathological” aging, that is, older individuals without identifiable diseases or conditions
(e.g., Alzheimer’s disease (AD), cerebral vascular disease) that negatively impact the central
nervous system. However, many would argue that there is a continuum between normal and
pathological cognitive aging. For example, a very large percentage of older individuals who
are cognitively normal manifest some degree of AD (especially amyloid) pathology [8–10]
and cerebrovascular disease [11].
Not surprisingly, there are a variety of definitions of successful cognitive aging. Given the
prevalence of dementia, successful aging could be defined as eluding the development of
dementia or mild cognitive impairment in the later years of life. A more ‘affirmative’
definition of successful cognitive aging would require that an individual performs in the top
tier relative to age-matched controls on cognitive tests. A problem with this definition is that
it would exclude individuals who were average performers at midlife and successfully
maintained their cognitive status in old age. One of the earliest and most influential
conceptualizations was offered by Rowe and Kahn [12] who emphasized the need to
recognize that older individuals are a very heterogeneous group, and conceived of successful
aging as reflecting minimal or no physiological decline compared to “average” younger
adults. By contrast, “super” cognitive aging could be viewed as reflecting performance at a
level en par with high functioning young adults.
THEORIES ABOUT THE AGING PROCESS AND COGNITIVE AGING
A simple (minded) definition of aging is that it reflects the process of getting older. Within a
more biological framework, aging reflects the process in which a variety of stressors are no
longer adequately counteracted by the body’s protective functions [13]. Fundamental
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tcomponents of the aging process involve damage from oxidative stress, diminished ability to
detoxify free radicals, decline in mitochondrial function, and accumulation of potentially
injurious proteins, all of which can lead to decreased integrity of neuronal membranes,
altered metabolic functions, and cell death [14–18].
Some investigators have argued that all components of the nervous system exhibit a similar
degree of age-related changes [19–21]. Others have suggested that there is selective
vulnerability of specific brain regions and systems, for example, the prefrontal cortex
(leading to impaired executive functioning) or subcortical white matter (leading to slowed
information processing) [22–26]. Some experts have emphasized the importance of age-
related changes in ascending neurotransmitter systems such as dopamine from the ventral
tegmental area [27,28] that have widespread effects on information processing.
DISTINGUISHING FACTORS WITHIN AND OUTSIDE OF OUR CONTROL
It has been pointed out that the more that successful aging is due to environmental and not
genetic factors, the more control people have to determine their health status and vitality as
they grow older [29]. Clearly, individuals do not have control over the genes in which they
inherit and intellectual capacities are strongly influenced by genetic factors. Based on twin
and other studies, some investigators have estimated that cognitive ability in old age is
significantly determined (approximately 50%) by the level of intelligence in childhood
[30,31]. In addition, there are major genetic factors that influence the development of age-
related biological diseases and processes. One example is the impact of a person’s
apolipoprotein E (ApoE) genotype status [30,32–34].
Studies also suggest that environmental factors account for a substantial portion of the
variance in successful aging. For example, an investigation of the Seventh-Day Adventists
estimated that optimal health-related behaviors can add approximately ten years to the
average life expectancy [35]. Below, we will discuss the potential beneficial impact of a
range of factors over which some degree of control can be exercised.
MAJOR AIMS OF THE CLINICAL APPROACH TO SUCCESSFUL COGNITIVE
AGING
Currently, the promotion of successful cognitive aging is linked to the dual goals of: 1)
preventing the loss of information processing capacity and cognitive reserve and 2)
enhancing brain capacity and cognitive reserve. Information processing capacity reflects the
efficiency and degree to which an individual can manage a range of cognitive, emotional,
and functional demands. Many theories about cognitive aging have posited an age-related
reduction in overall information processing capacity that reflects a decline in
neurophysiological function. Closely linked to the concept of information processing
capacity is that of “cognitive reserve” [36], which includes the ability to use brain networks
more proficiently in response to task demands, as well as the capacity to utilize alternative
cognitive strategies or neural networks in response to cerebral injury or decline.
Numerous conditions can undermine information processing capacity and make the brain
more vulnerable to additional insults. A simple model of brain capacity and deterioration
suggests that when the number of healthy functioning neurons or their connections
diminishes below a critical reserve level or threshold, individuals manifest symptoms of
cognitive impairment and eventually dementia [37–39] (see Figure 1). An excellent example
of the detrimental impact of cumulative insults to the central nervous system comes from
one of the “nun studies” [40], which investigated the occurrence of dementia in participants
with and without brain infarcts who met neuropathological criteria for AD. Those with brain
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tinfarcts had exhibited much poorer cognitive functioning and a higher prevalence of
dementia than those without infarcts. The authors concluded that cerebrovascular disease
plays an important role in determining the presence and severity of clinical symptoms of
AD.
There have been many other studies which validate the notion that systemic diseases or
conditions that impair cerebral function increase the likelihood that brain pathology will
manifest as cognitive impairment or frank dementia [41]. For example, obstructive sleep
apnea (OSA) may exacerbate cognitive dysfunction in patients with dementia [42].
Treatment of the OSA appears to improve some aspects of cognitive functioning in non-
demented older adults as well as those with dementia [42,43]. Of note, sleep-related
breathing disorders are very common in the elderly, with reports of prevalence rates between
24 and 42% [44].
Clinicians are in an excellent position to consider the presence of medical conditions that
may erode brain/cognitive reserve. For example, a recent publication from the Rush
Religious Orders Study reported that use of drugs with anticholinergic activity was
associated with a more rapid decline in cognitive performance in older individuals who were
studied over an average of 7.8 years [45]. Since many older patients are on a long list of
medications, it is appropriate to carefully review their potential cognitive side-effects. Other
conditions that can be addressed with patients include hypertension, diabetes, obesity, sleep
disorders, endocrine dysfunction, mood disorders, and potentially toxic substances.
Cognitive reserve is partially a reflection of intellectual capacity (IQ) and thus has a strong
genetic component. However, there is evidence that education, occupational experience, and
participation in ongoing intellectually stimulating activities help to determine reserve [46–
53]. Higher pre-morbid intelligence and more years of education have been associated with
a reduced risk of cognitive decline and dementia [47,49,50,54,55]. A study of 130 Catholic
clergy [56] during life and at autopsy suggested that individuals with more education
required more pathology (neuritic plaques) to reach any given level of cognitive impairment.
Moreover, education modified the degree to which AD pathology had a deleterious effect on
cognition (i.e., the association of pathology with cognitive function differed as a function of
years of education). Thus, education (and perhaps cognitive reserve in general) may not
simply increase the threshold for how much cerebral injury can be tolerated before
developing symptoms, but also mitigate the functional effects of brain injury, perhaps by
compensatory mechanisms such as functional reorganization or the utilization of alternative
networks. The beneficial effects of cognitive reserve do not only apply to neurodegenerative
disorders. For instance, a recent study that examined predictors of late cognitive decline
after penetrating head injury [57] found that pre-injury intellectual capacity was the most
consistent predictor of cognitive outcome across all phases of recovery and decline after
such injuries.
In the last decade, there has been growing support for the concept of cognitive reserve
through the use of functional imaging studies. Investigation of patients with dementia at the
same level of severity has revealed that those with more years of education tend to exhibit
much more severe reductions in cerebral blood flow to parietotemporal regions [51] and
greater amyloid burden, as measured by PiB imaging [58,59], than matched patients with
fewer years of education. These findings are consistent with the notion that patients with
more years of education have built enough cognitive reserve to be able to manage more
severe pathology. Other research has yielded analogous findings for occupational level and
the degree to which an individual had participated in intellectually stimulating life activities
[52,60]. Such findings serve as examples of “proof-of-concept” human studies regarding the
power of cognitive reserve.
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There are a number of different ways in which to examine whether a proposed factor may
have an impact on the promotion of successful cognitive aging. Four major lines of evidence
will be reviewed: 1) epidemiologic/cohort studies, 2) animal/basic science studies, 3) human
proof-of-concept studies, and 4) human intervention studies. For each line of evidence, we
will discuss advantages and limitations (Table 1) and provide several illustrative examples.
Epidemiological/cohort studies
The first major line of investigation involves epidemiological studies in which, for example,
a cohort of subjects is followed longitudinally and the potential impact of specified risk
factors on outcomes are determined, after trying to control for the influence of other
potentially relevant factors. The advantages of such studies include their large number of
subjects and their acquisition of information about many factors. Particularly valuable to the
study of successful cognitive aging is the ability of epidemiological studies to follow
subjects over years to decades. A major limitation to this line of investigation is that findings
can only establish the presence of an association between a designated factor and a clinical
outcome, which is not proof of causality. Uncertainty remains about the potential influence
of unidentified factors and whether an intervention directed at a particular factor would
necessarily change the outcome in clinically significant ways. For example, although
prospective cohort studies have indicated that treatment with estrogen or NSAIDs reduces
the risk of cognitive decline and dementia, these results have not been confirmed by
randomized controlled intervention studies [61–66].
Physical activity—There have been a growing number of longitudinal cohort studies that
have suggested that individuals who participate to a greater degree in physical activities are
at lower risk for developing cognitive impairment and dementia [67–69,69–74]. For
example, the Nurses’ Health Study, which examined over 18,000 women aged 70 to 81
years old, found that higher levels of physical activity were associated with better cognitive
performance on tests of general cognition, verbal memory, category fluency, and attention
[71]. The Honolulu-Asia Aging Study investigated the distance walked per day in more than
2,000 physically able men aged 71 to 93 years. After adjusting for age, men who walked the
least (<0.25 miles/day) experienced a 1.8-fold excess risk of dementia compared with those
who walked more than 2 miles/day [75]. Rovio and colleagues [76] from the Karolinska
Institute reported that vigorous leisure-time physical activity at midlife of at least twice a
week (each lasting 20–30 minutes) was associated with a reduced risk of dementia and AD
an average of 21 years later in a sample of over 1,400 adults, even after adjustments for age,
sex, education, follow-up time, locomotor disorders, ApoE genotype, vascular disorders,
smoking, and alcohol consumption. Exercise also has been shown to reduce the risk of
cerebrovascular events [77,78] which can undermine cognitive function.
Intellectually stimulating activity—Many studies that have indicated that as people age,
participation in intellectually stimulating activities may sustain cognitive functioning, create
a buffer against mental decline (presumably increasing cognitive reserve), and even promote
longevity [79–83]. Individuals who participate in cognitively stimulating activities (e.g.,
reading newspapers, playing games like checkers, chess, cards, or crossword puzzles) appear
to be at lower risk for developing probable AD [84,85] and mild cognitive impairment [86].
The causal direction of this association is difficult to prove. Perhaps, participation in fewer
activities is due to the early effects of an underlying neurodegenerative process. A potential
challenge to this hypothesis comes from studies like the Swedish Kungsholmen Project that
have baseline data on the leisure activities of subjects an average of 6 years prior to the
assessment of neuropsychological and functional status [87]. Even more convincing are
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tstudies that have found that increased participation in cognitively stimulating leisure
activities at mid-life is associated with decreased risk of developing clinical dementia many
decades later [76,88,89]. Interestingly, analogous results have been reported indicating that
the quality and extent of an individual’s social connections are predictive of cognitive
outcomes [90–92].
Vascular disease risk factors—Many longitudinal cohort studies have suggested that
individuals with higher levels of cardiovascular risk factors have a decreased likelihood of
manifesting successful aging, including successful cognitive aging. For example, the
Honolulu Asia Aging Study followed almost 6,000 Japanese-American middle-age men up
to 40 years. It suggested that the following factors measured at mid-life were associated with
successful aging: high grip strength, avoidance of hyperglycemia, hypertriglyceridemia,
hypertension, smoking, excessive alcohol consumption, and being overweight, and
attainment of higher years of education [93]. The “Study of Osteoporotic Fractures”
included almost 10,000 women whose mean age was 72 at baseline and 85 at follow-up
[94]. Those individuals who maintained their cognitive status were more likely to lack
diabetes, hypertension, smoking, and a limited social network, and to consume a moderate
amount of alcohol.
Several large prospective cohort studies have provided powerful epidemiological evidence
that untreated hypertension at mid-life increases the risk of subsequent dementia [95,96].
Moreover, a recently reported investigation of over 6,000 subjects suggested that use of
antihypertensive medications was associated with a reduced risk of dementia, especially in
subjects ≥75 years old (8% risk reduction per year of medication use) [97]. Analogous kinds
of data exist for the association between increased risk of developing dementia and high
body mass index or the metabolic syndrome [98–102]. For example, a recent study indicated
that a high body mass index at mid-life was a strong predictor of developing probable AD or
vascular dementia, independent of diabetes and other cardiovascular co-morbidities
[101,102]. In general, the greater the number of cardiovascular risk factors at mid-life (e.g.,
smoking, hypertension, high cholesterol, diabetes) the higher the risk of suffering from
dementia in late life [103].
Many epidemiological studies have reported that high cholesterol increases the risk of
developing dementia [104–106]. For instance, one study [107] followed over 1,400 middle-
age adults (mean age 50) for an average of 21 years and found that elevated total cholesterol
levels (≥6.5 mmol/L (251 mg/dL)) increased the odds of developing probable AD (odds
ratio 2.8), after adjusting for ApoE status, other midlife vascular risk factors, and other
confounders. However, other investigations, such as the Framingham Study [108], have
found no relationship between total cholesterol and the risk of incident AD. Recently, three
large cohort investigations concluded that statin use reduces the risk of the development of
dementia [109–111]. For example, the Rotterdam Study [110] followed close to 7,000
individuals prospectively over an average of 9 years. They reported a decreased risk of AD
(hazard ratio 0.57) among participants who used statins. Hazard ratios were similar for
lipophilic and hydrophilic statins. Non-statin cholesterol-lowering drugs did not reduce the
risk of incident AD. Sparks [111] reported a similar advantage for individuals who took
statins ‘electively’ as for those being treated for elevated cholesterol levels. However, the
beneficial impact of statins has not been a universal finding [112–114]. For example, in the
Religious Orders Study of over 900 older Catholic clergy [112], statin use at baseline did not
affect the risk of developing dementia in up to 12 years of follow-up; nor was it associated
with global cognitive status or performance in five separate cognitive domains. Other studies
using a time-dependent proportional hazards model, such as the Adult Change in Thought
study [113], have drawn similar conclusions. The cause of these discrepant findings is not
clear.
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tDiet/Nutrition—Although many studies have suggested that the nature of a person’s diet is
likely to have an impact on the risk of developing dementia, it has been very difficult to
determine which specific nutritional factors lower the risk of dementia or increase the
likelihood of successful cognitive aging. For example, reports have been inconsistent
regarding whether a high intake of vitamins E, C, B6, B12, folate, fish, or unsaturated fats is
linked to a lower risk of AD [115–119]. An alternative approach has been to examine
whether certain kinds of diets reduce the likelihood of developing a dementing illness
without trying to determine which specific dietary factors are most important. For example,
a recent study of over 2,000 community-dwelling non-demented individuals examined the
relationship between the degree to which individuals adhered to a Mediterranean diet and
their risk of developing probable AD [120]. The Mediterranean diet includes a high intake of
fruits and vegetables; monounsaturated fatty acids such as those found in olive oil; fish; nuts
and cereals; and relatively little consumption of red meat. Over the course of a 4 year
follow-up, higher adherence to the Mediterranean diet was linked to a lower risk of probable
AD, after adjusting for age, sex, ethnicity, education, ApoE genotype, caloric intake,
smoking, body mass index, and medical comorbidity. A follow-up study suggested that the
benefit of the Mediterranean diet was not simply due to greater physical activity among
individuals who consume healthier food, but represented an independent factor [73].
Whether adherence to the Mediterranean diet works through reducing the risk of vascular
disease, altering the neurobiological cascade associated with AD, or some other mechanism
remains to be determined [121]. In a subsequent study of patients diagnosed with mild
cognitive impairment, those who most closely adhered to a Mediterranean diet were less
likely to progress to a clinical dementia over the course of 4.5 years [122].
Alcohol consumption—The Rotterdam study [123], which followed close to 8,000 older
adults, reported that light to moderate alcohol consumption (i.e., 1–3 drinks/day) was
associated with a reduced risk of developing dementia. These results are consistent with a
recent meta-analysis of 22 longitudinal studies of alcohol use and incipient dementia/
cognitive decline that suggested that small amounts of alcohol may be protective against
dementia [124]. The definition of light to moderate alcohol consumption varied across
studies (from <1 to up to 28 glasses per week). Another recent study found that patients with
mild cognitive impairment who consumed moderate amounts of alcohol had a lower rate of
progression to clinical dementia than non-drinkers [125]. Many of these studies have not
differentiated between consumption of wine, beer, or hard liquor. There is some evidence to
suggest that wine may have a particularly salutary effect on brain and cardiovascular health,
and lower the risk of developing cognitive decline and dementia [126–130]. Differences
between red and white wine have not been systematically studied [124]. Potential
mechanisms may include its antioxidant, antithrombotic, vasodilating, and anti-amyloid
effects, which may in part be mediated by resveratrol, one of the active ingredients found in
red wine (see below) [129,131–133].
Basic Science/Animal Studies
The second major line of investigation involves animal and basic science research. This
work provides an opportunity to investigate questions under more highly controlled
conditions. For example, researchers can “enroll” animals in an intervention study, measure
the behavioral impact, and then sacrifice the animals to examine their brains. Potentially
pertinent changes in brain structure, synaptic connectivity, neurotransmitters and their
receptors, hormones, growth factors, and inflammatory markers can be measured. Cellular
and molecular effects can be investigated in the service of identifying underlying
mechanisms. There are important limitations to this approach. In-vitro systems tend to
reduce complex issues into simpler ones in order to study them. Findings from basic science
or animal models need to be translated to the study of humans. There are numerous
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texamples of research on drug development for human disorders in which interventions that
had worked in animals or in-vitro systems failed to do so in humans. There are very prudent
reasons why governmental regulatory agencies do not approve drugs based on in-vitro and
animal models alone, but require large-scale studies of human beings.
Physical activity—Studies of animals have indicated that exercise promotes neurogenesis
and synaptogenesis. Exercise upregulates the production of brain derived neurotrophic factor
(BDNF) [134–136]. BDNF is believed to help induce neurogenesis and promote survival
and/or neuronal differentiation. It has also been linked to long-term potentiation necessary
for memory formation. In addition, aerobic exercise in animals has been shown to release
two molecules, vascular endothelial growth factor and insulin-like growth factors, which
stimulate angiogenesis [134].
Cognitively stimulating/Enriched environment—There have been numerous studies
comparing animals placed in “enriched” versus standard environments. An enriched
environment often means a cage filled with potentially interesting junk to explore. The
opportunity of aging animals to interact with a more complex environment appears to
influence neurogenesis and dendritic complexity, and promote cognitive abilities and the
capacity to compensate for injury [137–141]. A study of transgenic AD mice exposed to an
enriched environment exhibited a marked reduction in cerebral Aβ levels and amyloid
deposits compared to animals reared under standard conditions [142]. The animals in the
enriched environment exhibited an increase in the activity of the Aβ-degrading protease,
neprilysin, and altered processing of the amyloid β-protein precursor (AβPP), reducing
amyloid burden. DNA microarray analysis revealed an upregulation in levels of transcripts
encoded by genes associated with learning, memory, vasculogenesis, neurogenesis, and cell
survival. In another recent study [143] using a mouse model of circumscribed neuronal
injury, animals placed in an enriched environment were able to re-establish learning
behavior and access long-term memories even after significant brain atrophy and
hippocampal neuronal loss. The environmental enrichment correlated with chromatin
modifications (increased histone acetylation) implicated in transcriptional regulation of gene
expression. Inhibitors of histone deacetylases reproduced the histone acetylation effects of
environmental enrichment and were associated with dendritic sprouting, increased synaptic
number, and the reestablishment of learning behavior.
Pharmacological agents—A myriad of medications, supplements, herbs, and vitamins
have been subjected to in vitro and animal studies to examine their potential to protect the
brain or enhance its cognitive functions. Below we limit our comments to just a few
representative examples, including statins, fish oil, resveratrol, and Ginkgo biloba. In part,
these were chosen because pertinent information is also available on them from
epidemiologic studies, human intervention studies of normal older adults, or both.
Statins (HM-CoA reductase inhibitors) have been shown to have pleiotropic effects
independent of their impact on cholesterol [144]. These effects include improvement of
endothelial function, inhibition of platelet activation, reduction of blood coagulability, and
suppression of inflammatory reactions [144–147]. In addition, there is in vivo evidence that
statins may modulate the metabolism of AβPP, reducing the production of Aβ [144].
Docosahexaenoic acid (DHA), a key component of fish oil, and its derivatives (DHA-
derived neuroprotectin D1) appear to have neurotrophic, antiapoptotic, and anti-
inflammatory signaling properties that affect neuronal survival and repair [148,149]. Animal
models suggest that DHA and its derivatives can diminish inflammatory responses
associated with colitis, peritonitis, and ischemic stroke [150].
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tResveratrol, a polyphenol found in grape skins and red wine, is believed to mimic caloric
restriction by stimulating sirtuins (SIRT1, Sir2) [151,152]. SIRT1 is deacetylase enzyme
that regulates the activity of transcriptional factors and proteins. It may activate intracellular
pathways critical for antioxidant activities, cell cycle regulation, mitochondrial energy
production, vascular tone, and oncogene suppression [132,133,152]. A seminal paper in
Nature [153] demonstrated that resveratrol extended the life span of yeast. Subsequent
studies found similar effects (prolongation of lifespan) in the worm, C. elegans, in the fruit
fly, and in aging fish (Nothobranchius furzeri). In mouse and rat experiments, anti-cancer,
anti-inflammatory, and glucose lowering effects have been demonstrated. Resveratrol
reportedly improved endurance in mice fed this compound for 15 weeks. There also is
evidence that resveratrol may interfere with amyloid plaque deposition and enhance Aβ
clearance [152,154].
Ginkgo biloba, which contains flavonoids, reportedly exhibits antioxidant activity as a free
radical scavenger and suppressor of active oxygen and nitrogen species [155–157].
Reportedly, it improves blood flow by influencing vasomotor function and inhibiting the
activation of platelets and smooth muscle cells, and has a modulatory effect on
neurotransmitters and their receptors. There also are reports suggesting that Ginkgo biloba
may inhibit the aggregation of Aβ [158].
Human Proof-of-Concept Studies
The third line of investigation involves what may be labeled human proof-of-concept studies
that examine markers of plasticity, reserve, efficiency, and neural compensation. For
example, differences in information processing among adults who vary in terms of degree of
successful cognitive aging are measured. Although the number of subjects studied is limited,
they often are investigated using the tools of modern cognitive neuroscience that can
elucidate potential underlying mechanisms. The results of such studies provide an
opportunity for further hypothesis generation and testing. At times, they have provided
clinicians with a rationale for trying certain interventions, even in the absence of randomized
controlled trials. The disadvantages are similar to research derived from basic science and
animal studies. Such studies may highlight links between certain factors and changes in
brain size or activity, but do not necessarily translate into improved function, clinical status,
or performance in daily activities.
Structural neuroimaging—Aerobic fitness is associated with greater white matter
integrity after controlling for age and gender [159]. This is an important finding, given the
growing evidence that age-related changes in white matter are associated with declines in
information processing speed and frontal-executive function [26,160–162]. Morphometric
MRI studies have provided evidence that cognitive activity or training alters brain
morphology of relevant structures, leading to an increase in cortical thickness. For example,
comparisons of the MRIs of individuals learning to juggle versus those of control subjects
reveal an increased size of bilateral mid-temporal grey matter and left posterior intra-parietal
sulcus, structures associated with the visual processing of movement [163]. Similarly,
comparisons of the MRIs of licensed London taxi drivers versus control subjects reveal
increased volume of the posterior hippocampus believed to help mediate spatial memory
[164].
Cognitively high and average performing older individuals exhibit differences in cortical
thickness. For example, older individuals who perform better on tests of fluid intelligence
have been shown to have a thicker cortex, especially within the posterior cingulate of the
right hemisphere, and the superior and middle frontal gyri, and gyrus rectus bilaterally
[165]. The authors hypothesized that age-related declines in efficiency of more specialized
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tcognitive processes may be compensated by an increase in monitoring and control in high
performing old adults. They argued that this cognitive activity itself may alter the brain
morphology of relevant structures, leading to an increase in cortical thickness in pertinent
areas.
Functional imaging—Positron emission tomography (PET) can image neurotransmitter
binding activity. Recently, there was a report in Science [166] that demonstrated that 14
hours of working memory training in young adult subjects over 5 weeks was associated with
decreases in prefrontal and parietal dopamine D1 receptor binding potential (larger
decreases in D1 binding potential correlated with larger improvements in working memory).
This was interpreted as indicating that the dopamine receptor system is plastic and can be
influenced by structured mental activity.
Functional magnetic resonance imaging (fMRI) has been used to examine the impact of
cognitive training on older adults. For example, Erickson and colleagues [167] conducted a
randomized, longitudinal dual-task training study in older subjects. They found that training
improved task performance and was associated with an increase in asymmetric hemispheric
activation (increase in left and decrease in right hemisphere activity within the ventral lateral
prefrontal cortex (PFC), and a decrease in age-related differences in the pattern of prefrontal
activation). Logan and colleagues [168] found that training which emphasized semantic
elaboration during a memory encoding task led to improved performance of older subjects.
This was associated with increased activity of the PFC (especially the left ventral region),
which, compared to young subjects, had been under-recruited at baseline, prior to training.
Both studies suggest that the aging brain can exhibit plasticity that may be influenced by
training and intervention programs.
Many functional imaging studies using glucose metabolism or cerebral blood flow have
reported age-related increases in frontal lobe activity (and unlike young subjects, the
recruitment of both hemispheres) in response to a number of task demands. In some cases,
these age-associated increases in neural activity and more widely distributed responses have
been interpreted as reflecting compensatory activity (in response to age-related declines in
physiological functioning). In other cases, they have been viewed as reflecting reduced
processing efficiency (i.e., diminished selective recruitment of specialized neural processes
[169]). To help sort out functional significance of age-related changes in neural activity,
investigators are increasingly dividing their subjects into groups based on task or
neuropsychological performance and then examining the differences between groups on
measures of neural function used to carry out the task.
A number of functional imaging studies have shown that older subjects who perform
comparably to young subjects on working memory, source memory, or episodic memory
tasks recruit more brain activity than young subjects and than old subjects who perform
worse [170–173]. However, this pattern is not associated with all cognitive functions (e.g.,
inhibitory control) [174,175] and some investigators would argue that older individuals who
perform the best often exhibit a pattern of activity on functional imaging closest to that of
younger adults [167,168]
Event-related potentials—Young adults with higher aerobic fitness tend to generate
larger amplitude and shorter latency P3 event-related potentials than less-fit subjects
[134,176]. This has been interpreted as consistent with the idea that greater physical fitness
or activity facilitates functions associated with the allocation of neural resources and with
more rapid information processing speed [134]. A more complex story emerges when
considering the interaction between fitness and age-related changes in the P3 component.
McDowell and colleagues [177] reported that low-active elderly participants generated
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tlarger P3 amplitude than observed in high-active old or either high- or low-active young
subjects. The authors concluded that higher levels of physical activity in the elderly may be
associated with a reduction in the neural resources needed to be allocated in response to
simple cognitive challenge.
Our lab has shown, using a subject-controlled visual novelty oddball paradigm, that
cognitively high performing old subjects generate a larger novelty P3 response than
cognitively high performing middle age and young subjects and than cognitively average
performing old subjects [80,82,178]. These electrophysiological results occur in the context
of behavioral findings that cognitively high performing old subjects are as engaged by
novelty as their cognitively high performing younger counterparts and more engaged by
novelty than cognitively average performing old adults. Across the older participants, the
better the performance on tests of frontal-executive function, the larger the P3 amplitude in
response to novel stimuli (and the more time they spent viewing novel stimuli). These
results provide a strong basis for arguing that the larger P3 response to novel stimuli
observed in cognitively high performing old adults does not simply represent less efficient
processing, but a successful compensatory mechanism, presumably in response to other age-
related physiological changes.
Human Intervention Studies
The final line of investigation involves intervention studies in human subjects. Ideally,
baseline measures are obtained, individuals are randomized to treatment or placebo groups,
and outcomes are measured to establish treatment effects. The potential variables
investigated can include cognitive performance and biological or neuroimaging markers.
Many would consider these kinds of studies to be the “gold standard” for proof of a factor’s
impact on successful cognitive aging. However, there are challenges and limitations to such
an approach. For example, to what extent can the observed effects be generalized? How long
do the effects endure and to what extent are they clinically relevant? How feasible is it to
translate such interventions into practice outside of a controlled study? Also, some of the
most pertinent kinds of studies (e.g., impact on developing dementia late in life of
antihypertensive treatment versus placebo in middle-aged subjects with hypertension) often
are not feasible for financial, logistical, or ethical reasons.
Exercise/Physical training—A Cochrane Database System Review [179] noted that 8
out of 11 randomized controlled exercise intervention studies reported that structured
aerobic exercise interventions resulted in increased cardiorespiratory fitness of the
intervention group, with an average improvement of approximately 14%. Most studies
involved approximately 1 hour of exercise 3 times per week. This improvement was
associated with better performance in cognitive functions, including auditory attention
(effect size 0.52), speed of information processing (effect size 0.26), and visual attention
(effect size 0.26). A recent review article by Hillman, Erickson, and Kramer [134]
concluded that physical activity improved cognition in both normal older adults and patients
with early AD. Although benefits were seen for a range of cognitive functions, there
appeared to be disproportionate improvement in executive control (including planning,
working memory, and multi-tasking).
Particularly intriguing are the exercise intervention studies that have looked at effects on not
only cognition but also underlying brain structure and activity. For instance, in a study
reported by Colcombe and colleagues [180], older individuals who participated in an aerobic
training group for 6 months (i.e., ~1 hour, 3 times per week) exhibited significant increases
in the size of components of the prefrontal cortex and superior temporal lobes. In another
study by the same researchers [181], more physically fit older subjects as well as those
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trandomly assigned to participate in the aerobic fitness training group (~45 minutes of
walking, 3 times per week) for 6 months performed better on an attention task (more
efficient response to conflicting cues on a flanker task). Moreover, fMRI revealed that they
exhibited greater neural activity in regions associated with attentional control (middle and
superior frontal gyrus, superior parietal lobule) and less activity in the anterior cingulate
cortex.
Cognitive training—The potential impact of cognitive training on older adults has been a
topic of increasing interest [182–186]. One of the greatest challenges is trying to
demonstrate that the training results in changes outside of the laboratory that are applicable
to everyday life. To date, there have been no reports to suggest that cognitive training
programs of older adults reduce the risk of developing a clinical dementia. Rather, the
emphasis has been on establishing that cognitive training can improve measures of
intellectual performance and daily activities. For example, in a study by Ball and colleagues
[182], 2,832 older individuals (65–94 years old) were randomly assigned to one of three
training groups for memory (verbal episodic memory), reasoning (problem-solving that
follows a serial pattern), or speed of processing (visual search and identification), or to a
control group. The initial intervention improved performance relative to baseline, however,
the improvement was limited to the cognitive realm that had been targeted. Improvements
lasted through the 2 years of follow-up. Fifty percent of the random sample was given
booster training (four 75 minute sessions over 2–3 weeks) 11 months after the initial training
period. Booster training increased the training improvements in speed and reasoning, which
were maintained at the 2-year follow-up. Training was not shown to have a measurable
impact on everyday functioning at 2 years. In a 5-year follow-up study [183], the
investigators reported that each intervention had maintained effects on the targeted cognitive
ability. On a self-report survey of instrumental activities of daily living, all three
intervention groups indicated less difficulty than the control group, which only reached
significance for the reasoning group. Also, only the booster training for speed of processing
showed an effect on performance-based functional measures of everyday processing speed.
There are a growing number of cognitive training programs that are being marketed to older
adults. Many provide little, if any, data to support the claims being made about the particular
program being promoted. Moreover, to date, there is no clear evidence to suggest that formal
cognitive training programs are more effective than traditional forms of intellectually
stimulating activities (e.g., crossword puzzles, challenging reading, card games, etc.); nor
have there been published head-to-head studies comparing one commercially-available
program to another. Several other important issues have not yet been addressed, including
the potential impact of a training program that titrates difficulty to a participant’s current
level of success, the game-like, competitive features of a program, and the effect of a
participant’s desire to get a good return-on-investment for the cost of purchasing the
software.
Pharmacologic agents—Numerous agents have been proposed to provide
neuroprotection (by counteracting hypothesized underlying injurious age-related processes),
cerebral enhancement (by counteracting deleterious consequences of the aging process
through boosting neurotransmitters, hormones, or cerebral blood flow), or both. Table 2
provides a partial list of such agents. A selected few will be reviewed here.
Anti-hypertensive drug treatment: As noted before, there is strong epidemiological
evidence that hypertension increases the risk of dementia. Recently, there have been four
randomized placebo-controlled studies investigating the effects of anti-hypertensive agents
on the incidence of dementia in older individuals [187,188]. The systolic hypertension in
Europe (SYST-EUR) study [189] suggested that active treatment with nitrendipine,
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tenalapril, and/or HCTZ reduced the rate of dementia by approximately 50%. The
Perindopril Protection Against Recurrent Stroke Study (PROGRESS) [190,191] found that
treatment with perindopril and indapamide was associated with a reduction in cognitive
decline compared to placebo (relative risk 19%). In contrast, two other studies did not
demonstrate an advantage to treatment with anti-hypertensive medication. The Systolic
Hypertension in the Elderly Program (SHEP) subjects received chlorthalidone, atenolol, or
reserpine (versus placebo) [192,193] and the Study on Cognition and Prognosis in the
Elderly (SCOPE) [194] (candesartan versus placebo) did not demonstrate a significant
difference between treatment and placebo groups in change in MMSE score or the incidence
of dementia. Of note, there were problems with the analysis of data because of the number
of patients on placebo who were given active treatment (e.g., 84% in the SCOPE trial). In
addition the trials were not very long (2–4.5 years) and the hypertensive subjects treated
were not middle-aged, but older. It is very plausible that the most effective way for
antihypertensive treatment to reduce the risk of dementia will be to intervene early (e.g., in
middle-age).
Statins: As mentioned previously, statins are reported to have multiple effects independent
of their impact on cholesterol, including suppression of inflammatory reactions, inhibition of
platelet activation, reduction of blood coagulability, and modulation of the metabolism of
AβPP. In addition, several cohort investigations have found that individuals who take statins
have a lower risk of becoming demented [109–111]. There have been two very large
prospective intervention studies, the PROSPER study [195] that included almost 6,000
participants randomized to pravastatin or placebo, and the Heart Protection Study
Collaborative Group [196] that followed over 20,000 adults randomly assigned to
simvastain or placebo. The main purpose of these studies was to understand the relationship
between statin use and the risk of coronary artery disease and other vascular events.
However, both reported on the cognitive effects and found no clear cognitive benefit from
being on statins. For example, the PROSPER study compared baseline cognitive
performance to last on-treatment cognitive performance an average of 3.2 years later. No
significant group differences (treated versus placebo) were found in changes in MMSE score
or performance on tests of attention and memory.
A small study (n = 97) conducted by Parale et al. [197] aimed to assess the cognitive impact
of a statin by comparing subjects on atorvastatin versus placebo who were matched for age,
gender, education, and the presence of hypertension and diabetes. Changes between baseline
and six months were measured in five cognitive domains. Subjects treated with the statin
scored significantly better than the placebo group on tests of psychomotor speed, mental
flexibility, working memory, and memory retrieval. Clearly more research is needed to
determine the extent to which treatment with statins reduces the likelihood of developing
dementia and helps to preserve cognitive function, especially if used over many years.
Antioxidants: As discussed earlier, one of the major theories about the aging process posits
a central role for cellular injury due to oxidative stress. Thus, it is not surprising that many
agents with potential antioxidant properties have been considered (including vitamin E,
vitamin C, beta carotene, folic extract, curcumin, and green tea). The results of most trials to
date have been disappointing [198]. Table 3 summarizes major studies that have investigated
the impact of antioxidants on cognitive status in healthy older adults or those with mild
cognitive impairment, none of which reported beneficial results. Thus, despite its strong
intuitive appeal, we do not yet have convincing evidence to support the use of antioxidant
supplementation to augment or maintain cognitive status in cognitively normal adults or
those diagnosed with mild cognitive impairment.
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tA similar conclusion can be drawn about omega-3 fatty acids (fish oil), which, as reviewed
earlier, theoretically can reduce oxidative damage, inflammation, and risk of vascular injury.
A Cochrane Database review in 2006 [199] suggested that up to that point there had been no
randomized, placebo-controlled, double-blind studies that lasted a minimum of 6 months in
persons 60 years and older without pre-existing dementia and established cognitive
endpoints. However, recently there was a double-blind placebo-controlled trial [200] in
which 302 cognitively healthy older individuals were assigned to 1,800 mg or 400 mg per
day of eicosapentaenoic acid and docosahexaenoic acid (EPA-DHA) versus placebo for 6
months (Table 3). There was no evidence of an effect on cognitive performance in the
treatment compared to the placebo groups. It remains to be determined if cognitive benefits
are derived from taking omega-3 fatty acids for more than 6 months.
There has been an escalating interest in resveratrol, a compound found in red wine that has
been shown to extend the life span of yeast, fruit flies, and other animals. As mentioned
previously, there have been many provocative in vivo and animal studies. However, there
have been no published controlled studies of the impact of resveratrol on human
neurodegenerative diseases, on age-related cognitive changes, nor on its ability to increase
physical endurance in humans. It remains to be determined if the promise of resveratrol will
be fulfilled. Of note, despite the limited data on humans, there has been little hesitation to
market resveratrol as a ticket to the “fountain of youth” [201–203].
Ginkgo biloba: Ginkgo biloba is purported to have a number of potentially useful cognitive
enhancing and cerebral protective properties, including mild stimulant effects, antioxidant
properties, increased cerebral blood flow, and inhibition of platelet activating factor. A
recently reported study by DeKosky and colleagues [204] examined 2,069 older community
volunteers (>75 years old) with either normal cognition or mild cognitive impairment (Table
3). Treatment with Gingko biloba was not found to be effective in reducing either the overall
rate of developing dementia or AD in older individuals with normal cognition or those with
mild cognitive impairment over a mean follow-up of 6.1 years.
The potential impact of Ginkgo biloba on healthy, cognitively normal adults under age 60
also has been investigated. A systematic review done by Canter and Ernst [205] evaluated
15 randomized clinical trials, of which 7 were single dose and 8 were longer term studies,
ranging from days to weeks. The authors found no convincing evidence for a robust positive
effect of Ginkgo biloba on any aspect of cognition in healthy younger adults. Solomon and
colleagues [206] investigated healthy older community-dwelling men and women who were
randomized Ginkgo biloba or placebo (Table 3). The investigators purposefully chose the
dose of Ginkgo and the duration of study to match the manufacturer’s recommendations that
promised to improve attention, memory, and related cognitive functions within as little as 4
weeks. However, no benefits were found in any outcome measure, which included tests of
verbal and nonverbal learning and memory, verbal fluency, language, and attention,
participants’ self-report on a memory questionnaire, and global rating by spouses, friends, or
relatives. In summary, barring new evidence, one cannot recommend the use of Ginkgo
biloba to enhance cognition in older individuals.
DISCUSSION
Promoting successful cognitive aging is a topic of profound importance to both individuals
and the field of public health. Different patterns of cognitive aging have been identified and
there is a growing need to better understand what influences these trajectories. Although
genetic factors play an important role in determining intellectual capacity and in
predisposing an individual to a variety of age-related disorders, there are numerous factors
over which we can exercise some degree of control. Clinicians can play an important role in
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tidentifying and treating conditions that reduce cognitive reserve and intellectual capacity,
including vascular risk factors, sleep disorders, metabolic dysfunction, mood disorders, and
side-effects from medication. They can serve as advocates for and educators about brain
health and well-being. In order to accomplish this, clinicians need a framework for
evaluating claims made about current and future cognitive enhancing activities and agents.
This paper reviewed different approaches to the investigation of whether a proposed factor
actually promotes successful cognitive aging. In many cases, it is essential to acknowledge
that the currently available evidence is insufficient and that further investigation is required.
Pertinent data may be obtained from epidemiological/cohort studies, basic science and
animal investigations, human proof-of-concept studies, and randomized controlled trials in
humans. These approaches provide different perspectives upon which to evaluate the factors
under consideration. Each approach has its advantages and limitations. Often, the most
convincing case in favor of a factor’s impact on successful cognitive aging will be made
through lines of converging evidence. Table 4 summarizes the relative progress that has
been made in the evaluation of a few selected factors that can serve as examples.
Currently, the strongest case can be made for physical and cognitively stimulating activities,
both of which appear to be able to enhance cognitive performance and reduce the likelihood
of developing dementia. Epidemiologic studies suggest that regular exercise and
participation in cognitively stimulating activities diminish the risk of dementia. Animal
studies suggest that exercise is associated with the upregulation of relevant neural growth
factors such as BDNF, and that environmental enrichment promotes neurogenesis, increases
the capacity to compensate for cerebral insults, and augments cognitive function. Proof-of-
concept studies highlight the plasticity of the human brain, even in older adults. For
example, compared to their age-matched counterparts, better-fit and more cognitively
competent individuals exhibit differences in brain structure, neural activity, and
electrophysiology that appear to be more adaptive. Cognitive experience or mental practice
influences the size of pertinent brain regions and modulates neurotransmitter activity.
Randomized controlled intervention studies suggest that aerobic exercise and cognitive
training programs are associated with improved cognitive performance and can affect
relevant biological markers.
There are several barriers to translating knowledge about factors that may promote
successful cognitive aging into real world practice. First, more research is needed to move
from general principles derived from scientific studies to concrete clinical recommendations.
Clinicians tend to be a practical group who wants to know the “bottom line” regarding
recommendations for patient care. For example, in addition to appreciating that exercise is
good for brain health, there is an interest in determining the minimal amount of exercise a
person can do to be of benefit. Secondly, more research is needed to determine the most
effective strategies and interventions for encouraging individuals to adopt healthier
lifestyles, especially if such changes are perceived as effortful or burdensome. Specifically,
how can we influence individuals or groups of individuals to sustain engagement in
activities that promote cognitive well-being?
Appealing solely to the advancement of one’s personal health may motivate a relatively
small, self-selected group and not serve as a foundation for public policy or clinical care
[207]. It seems intuitively obvious (but in need of scientific verification) that activities that
are experienced as being intrinsically enjoyable or meaningful are the ones in which people
are most likely to participate and remain engaged over time. For instance, it seems much
more probable that individuals would continue to play bridge or cards over the course of
their adult lives because they enjoyed them than because these activities are theoretically
good for their cognitive health. Many leisure activities represent a combination of mental,
Daffner Page 15
J Alzheimers Dis. Author manuscript; available in PMC 2011 June 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tphysical, and social components [208]. For example, bridge or card playing can be both
intellectually and socially stimulating. Participation in sports can provide an opportunity for
both aerobic exercise and social interactions. There is epidemiological support for the notion
that the most beneficial effects may be derived from participating in a range of activities that
involve a mixture of intellectual, physical, and social components [208]. Moreover,
activities that reflect a combination of attributes may provide a powerful motivational hook
for maintaining participation. Another promising strategy has been to harness the desire of
older individuals to feel generative, have an impact on others, and remain socially active
[72,74]. The Baltimore Experience Corp is a novel, real-world intervention research
program in which 149 older subjects were randomly assigned to a wait-list control group or
to one that helps elementary school children with reading achievement, library support, and
classroom behavior for 15 hours per week during the academic year. The participants
included a disproportionate number of African Americans with relatively low income and
education. Pilot data suggest that participants remained actively engaged with the program
over many months and tended to show improvements in executive functions and memory,
especially those individuals who were the least cognitively competent at baseline.
Converging lines of evidence, as illustrated by research on physical and cognitively
stimulating activities, may be most convincing and provide a means of addressing the
limitations associated with any single avenue of study. However, in many cases it is
unrealistic to expect that all of the different research approaches will provide pertinent input.
What should clinicians do while they wait for the results from randomized controlled trials
that may never take place or at least not occur for many years? Should clinicians provide
advice based on available evidence derived from epidemiological investigations, basic
science and animal work, and/or human proof-of-concept studies? Like many issues in
clinical medicine, it is necessary to weigh potential risks and benefits, be aware of the limits
of current data, and modify suggestions as new information becomes available. Here are
some provisional recommendations. Despite the absence of randomized clinical trials,
available epidemiological data and knowledge about the relationships between untreated
hypertension, cerebrovascular disease, and cognitive decline provide a powerful justification
to advocate for aggressive treatment of hypertension and other vascular risk factors by
middle-age or earlier. Although epidemiological evidence seems to favor the use of statins
to lower the risk of dementia, more definitive recommendations await randomized
controlled studies that ideally would be conducted over many years. Currently, there is no
clear evidence that antioxidants or Ginkgo biloba promote successful cognitive aging. The
impact of resveratrol, DHA, and a long list of other proposed agents (Table 2) remains to be
determined.
Major efforts should be made to ensure transparency about what is known versus what is
speculative, and to translate this information into language that is accessible to the public
that lacks expertise or professional training in this field. Unfortunately, these kinds of
distinctions are very rarely made explicit by advertising campaigns that market nutraceutical
agents. Rather, they tend to promulgate the most favorable bits of information while
disregarding salient limitations of available data. Despite an interest in enhancing cognitive
performance and avoiding dementia, many aging individuals may not ardently pursue
physical or intellectual activities because of diminished motivation or related issues, but
rather opt for the hypothetical and often hyped benefits of pills, medications, or supplements
that are being promoted. Such individuals are at risk for becoming targets of very strong
marketing campaigns from the nutraceutical industry. The worldwide nutraceutical industry
is flourishing. Currently, it is estimated that the nutraceutical industry is a $120 billion a
year business (evenly distributed between supplements, foods, and beverages) [209]. It is
very likely that this industry will continue to grow in the future. It is currently legal to
market products as “brain boosters” or “memory enhancers” without proof of efficacy, if no
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tclaims are made about being effective in the cure or treatment of illness [210]. Although a
number of agents seem promising, for many of them (e.g., Ginkgo biloba, resveratrol) the
current claims are not substantiated by research in humans. Clearly, there is a need for many
more well-designed studies to adequately address the outstanding questions of this field.
There are numerous challenges to such a research endeavor. Who will fund these studies,
especially if the nutraceutical industry can market its products without being required to
substantiate claims through rigorous scientific investigation? Does a study’s failure to
demonstrate efficacy “prove” that the agent is not beneficial? To what extent might the
negative outcome of a study have been different if the investigators had used an alternative
dose of the agent for a different duration of time in a different population of subjects? Did
the study have adequate statistical power? Even if the results are statistically significant, on
what grounds do we determine whether they are clinically relevant? Of course, these issues
are the same ones faced by any clinical trial attempting to investigate the efficacy of a
medication. Despite the fact that the risks of many proposed cognitive enhancers are claimed
to be low and are directed at healthy individuals, not patients, serious consideration should
be given to holding these agents to the same high standards of proof as other kinds of drugs
in the field of medicine. In conclusion, given the persistent yearning of individuals not only
to live longer, but also to age successfully, health care professionals need to be in a position
to understand the pertinent issues, provide thoughtful recommendations, and help to educate
and protect the public.
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Illustration of the impact on cognitive functioning of processes injurious to the brain. The
cognitive functioning curve is shifted downward, leading patients to cross the threshold for
clinical dementia earlier. Clinicians should aggressively treat conditions that have the
potential to reduce cognitive reserve and information processing capacity, such as
hypertension, diabetes, sleep disorders, and side-effects from medication.
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Table 1
Advantages and limitations of different lines of evidence
Lines of Evidence Advantages Limitations Examples
Epidemiological/Cohort Studies • Large number of
subjects
• Data on multiple
factors
• Longitudinal
follow-up over
many years
• Association
not causation
• Uncertainty
about the
influence of
unidentified
factors
• Uncertainty
about whether
an intervention
aimed at an
identified
factor would
have an impact
on clinical
outcome
• Physical activity
• Intellectually stimulating
activity
• Diet/Nutrition
• Alcohol consumption
Basic Science/Animal Studies • Investigation under
highly controlled
conditions
• Determination of
underlying
mechanisms
• Identification of
intervening
variables (e.g.,
changes in brain
structure,
neurotransmitters,
growth factors,
inflammatory
markers, etc.)
• Reduction of
complex issues
into simple
ones
• Need to
translate
findings from
basic science
or animal
models to the
study of
humans
• Defining
underlying
mechanisms
does not
signify that
manipulating
an identified
factor will alter
clinical
outcome
• Physical activity
• Enriched/stimulating
environment
• Pharmacological agents
– Statins
– DHA
– Resveratrol
– Ginkgo biloba
Human “Proof- of-Concept”
Studies
• Opportunity to
examine markers of
cerebral plasticity,
reserve, efficiency,
and neural
compensation
• Utilization of the
tools of cognitive
neuroscience to
elucidate
underlying
mechanisms
• Opportunity for
further hypothesis
testing and
generation
• Similar to the
limitations
associated with
basic science/
animal studies
noted above
• Structural Imaging
– Cognitive or
fitness training
and alterations in
brain structure
• Functional Imaging
– Cognitive training
and
neurotransmitter
binding or
changes in
correlates of
neural activity
• Event- Related Potentials
– Aerobic Fitness
and markers of
resource
allocation and
processing speed
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Lines of Evidence Advantages Limitations Examples
– Differences in
resource
allocation between
cognitively high
vs. average
performers
Human Intervention Studies • Often considered
the ‘gold standard’
• Randomization
helps control for
selection bias and
other variables that
may influence
clinical outcomes
• Outcome measures
can include
cognitive
performance as
well as biological
or neuroimaging
markers
• Feasibility of
conducting
such studies
for financial,
logistical, or
ethical reasons
• Uncertainty
about the
extent to which
the observed
effects can be
generalized
• Uncertainty
about whether
statistically
significant
results are
clinically
relevant
• Uncertainty
about whether
a failed trial
was due to the
particular dose/
duration of an
agent, or the
particular
sample studied
• Exercise/Physical training
• Cognitive training
• Pharmacologic agents
– Antihypertensive
medication
– Statins
– Antioxidants
– DHA
– Ginkgo biloba
Key: DHA= docosahexaenoic acid
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Table 2
Proposed cerebral enhancing/protective agents
Proposed Cerebral Enhancing
Agents
Proposed Cerebral
Protective Agents
Proposed agents with both cerebral enhancing and protective
properties
Ampakines Antioxidants Acetyl-L-carnitine
Cholinesterase Inhibitors Omega-3 fatty acids (fish
oil; EPA-DHA)
B vitamins (B6, B12, Folate)
CREB Resveratrol CDP- Choline
Hydergine Statins Cerebrolysin
Modafinil Gamma- aminobuteyric acid
Piracetam Ginkgo biloba
Stimulant medications Ginseng
Hormonal replacement/supplementation
Pentoxifylline
Phosphatidylserine
Phospolipids
Selegeline
Vinpocetine
Key: CREB= cAMP response element binding; EPA-DHA= eicosapentaenoic acid and docosahexaenoic acid
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Table 3
Randomized controlled studies of antioxidants, fish oil, and Ginkgo biloba
Study Agent(s) Subjects Duration Major Findings
Petersen et al., 2005 Vitamin E
1000 IU 2×/day
769 older adults (55–90)
with MCI
3 years No impact on progression to
dementia
Heart Protection Study
Group (2002)
Vitamin E 600 IU/day
Vitamin C 250 mg/day
Beta carotene 20 mg
20,536 older adults (40–
80)
5 years No impact on cognitive status
Yaffe et al., 2004
(AREDS)
Vitamin E 400 IU/day
Vitamin C 500 mg/day
Beta carotene 15 mg/day
2,166 older adults (61–87) 6.9 years No effect on cognitive
performance
Kang et al. 2006
(Women’s Health Study)
Vitamin E 600 IU on alternate days 13,807 older women (70–
81)
9 years No effect on cognitive
performance
van de Rest, 2008 EPA-DHA
1,800 mg/day or 400 mg/day
302 older adults (65+) 26 weeks No effect on cognitive
performance
DeKosky et al. (2008) Ginkgo biloba 120 mg 2×/day 2,069 older adults with
normal cognition or MCI
(75+)
6.1 years No impact on progression to
dementia
Solomon et al. (2002) Ginkgo biloba 40 mg 3×/day 230 older adults (>60) 6 weeks No effect on cognitive
performance
Key: IU= international units; AREDS= Age-Related Eye Disease Study Research Group; EPA-DHA= eicosapentaenoic acid and docosahexaenoic
acid; MCI= mild cognitive impairment
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Table 4
Relative progress along 4 major lines of evidence of selected factors proposed to promote successful cognitive
aging
Factor Epidemiological Cohort Studies Animal/Basic Science Studies Human Proof of Concept RCTs
Exercise + + + + + + + + + + + + +
Intellectual Stimulation + + + + + + + + +
Cholesterol/Statins + + − + + N/A − − +
Ginkgo biloba N/A + + N/A − −
Resveratrol + + + + N/A N/A
DHA + + + N/A −
Antioxidants + + − + + N/A − −
Diet/Nutrition + + + N/A N/A
Key: RCT= randomized controlled trials; DHA = docosahexaenoic acid; N/A= Not applicable, data not yet available
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